FDA Inspection 1095778 — RePharm LLC

RePharm LLC — FEI 3015474688

The FDA completed an inspection of RePharm LLC on July 3, 2019 in Riverside, MO. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 7 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
July 3, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Riverside, MO (United States)

Citations

IDCFRDescription
111221 CFR 211.25(a)Training--operations, GMPs, written procedures
127421 CFR 211.68(a)Calibration/Inspection/Checking not done
163321 CFR 211.130(d)Examination of packaging and labeling
192621 CFR 211.166(b)Adequate number of batches on stability
202621 CFR 211.192Quality control unit review of records
202721 CFR 211.192Investigations of discrepancies, failures
357021 CFR 211.100(a)Approval and review of procedures